Wockhardt Limited
WOCKPHARMA
株式のランク
#4502
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
株価
$21.02
時価総額
$3.42B
変化（1日）
-2.48%
変化（1年）
37.78%
国
IN
取引 Wockhardt Limited (WOCKPHARMA)
カテゴリー
Healthcare
Wockhardt Limited（WOCKPHARMA）の営業利益率
October 2026 時点の営業利益率 TTM: 13.78%
Wockhardt Limited の最新の財務報告と株価によると、現在の営業利益率（TTM）は 13.78% です。2024 年末時点では 29.55% でした。
Wockhardt Limited の営業利益率の履歴（2004 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 13.78% | -60.31% |
| 2025 | 34.72% | 17.50% |
| 2024 | 29.55% | -555.32% |
| 2023 | -6.49% | -769.07% |
| 2022 | 0.97% | -108.37% |
| 2021 | -11.59% | 252.28% |
| 2020 | -3.29% | 338.67% |
| 2019 | -0.75% | -85.60% |
| 2018 | -5.21% | 70.26% |
| 2017 | -3.06% | -136.34% |
| 2016 | 8.42% | -44.64% |
| 2015 | 15.21% | -12.54% |
| 2014 | 17.39% | -50.41% |
| 2013 | 35.07% | 21.64% |
| 2012 | 28.83% | 33.84% |
| 2011 | 21.54% | 37.64% |
| 2010 | 15.65% | -23.62% |
| 2008 | 20.49% | -4.87% |
| 2007 | 21.54% | -3,091.67% |
| 2006 | -0.72% | -136.36% |
| 2005 | 1.98% | -89.48% |
| 2004 | 18.82% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 62.34% | -95.48% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.94% |
US
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。